Vanguard Group Inc X Biotech Inc. Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in X Biotech Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,036,969 shares of XBIT stock, worth $7.57 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,036,969

Previous 895,315 15.82%

Holding current value

$7.57 Million

Previous $7.28 Million 26.77%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$4.54 - $9.89 $643,109 - $1.4 Million	141,654 Added 15.82%	1,036,969 $5.33 Million
Q1 2024 May 10, 2024	BUY	$4.03 - $8.13 $55,630 - $112,226	13,804 Added 1.57%	895,315 $7.28 Million
Q4 2023 Feb 14, 2024	BUY	$3.56 - $4.65 $32,282 - $42,166	9,068 Added 1.04%	881,511 $3.53 Million
Q2 2023 Aug 14, 2023	BUY	$3.06 - $6.38 $55,000 - $114,674	17,974 Added 2.1%	872,443 $5.18 Million
Q4 2022 Feb 10, 2023	BUY	$3.03 - $3.79 $1,066 - $1,334	352 Added 0.04%	854,469 $3 Million
Q3 2022 Nov 14, 2022	SELL	$3.58 - $5.88 $630 - $1,034	-176 Reduced 0.02%	854,117 $3.09 Million
Q2 2022 Aug 12, 2022	SELL	$5.13 - $9.2 $381,589 - $684,332	-74,384 Reduced 8.01%	854,293 $4.81 Million
Q1 2022 May 13, 2022	SELL	$8.64 - $11.71 $104,803 - $142,042	-12,130 Reduced 1.29%	928,677 $8.02 Million
Q4 2021 Feb 14, 2022	BUY	$10.95 - $16.07 $611,283 - $897,107	55,825 Added 6.31%	940,807 $10.5 Million
Q3 2021 Nov 12, 2021	BUY	$12.95 - $18.24 $434,679 - $612,243	33,566 Added 3.94%	884,982 $11.5 Million
Q2 2021 Aug 13, 2021	BUY	$15.83 - $17.84 $13.5 Million - $15.2 Million	851,416 New	851,416 $14.1 Million

Others Institutions Holding XBIT

# of Institutions

Shares Held

4.65M

Call Options Held

5.8K

Put Options Held

4.6K

View Full List

About XBiotech Inc.

Ticker XBIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,439,300
Market Cap $222M
Description
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical...

More about XBIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc X Biotech Inc. Transaction History